MRE11 and cancer: To determine whether AKT activation is indeed the downstream effector of MRE11, MRE11-overexpressed cells were treated with wortmannin, a PI3K/AKT inhibitor, and the result showed that MRE11-induced cancer cell migration was indeed blocked by cotreatment with wortmannin (Fig. 4H).